Stockscreener 앱 받기
20.77
9.20%
1.75
시간 외 거래:
20.98
0.21
+1.01%
전일 마감가:
$19.02
열려 있는:
$18.94
하루 거래량:
728.01K
Relative Volume:
2.82
시가총액:
$557.00M
수익:
$70.32M
순이익/손실:
$-6.68M
주가수익비율:
-83.38
EPS:
-0.2491
순현금흐름:
$12.89M
1주 성능:
+9.20%
1개월 성능:
+14.00%
6개월 성능:
+13.25%
1년 성능:
+39.58%
1일 변동 폭
$18.91
$20.80
1주일 범위
$18.50
$20.80
52주 변동 폭
$11.09
$23.00
Eton Pharmaceuticals Inc Stock (ETON) Company Profile
명칭
Eton Pharmaceuticals Inc
전화
(847) 787-7361
주소
21925 W. FIELD PARKWAY, DEER PARK, IL
Compare ETON vs TAK, ZTS, HLN, TEVA, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ETON
Eton Pharmaceuticals Inc
|
20.77 | 510.07M | 70.32M | -6.68M | 12.89M | -0.2491 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.11 | 56.96B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
115.99 | 49.54B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.23 | 45.90B | 14.54B | 2.22B | 2.58B | 0.4871 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.44 | 34.48B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
527.00 | 23.24B | 3.18B | 1.33B | 1.04B | 27.90 |
Eton Pharmaceuticals Inc Stock (ETON) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-23 | 재확인 | H.C. Wainwright | Buy |
| 2025-01-10 | 개시 | B. Riley Securities | Buy |
| 2025-01-06 | 재확인 | H.C. Wainwright | Buy |
| 2024-09-04 | 재개 | H.C. Wainwright | Buy |
| 2024-05-06 | 개시 | Craig Hallum | Buy |
| 2021-10-14 | 재개 | B. Riley Securities | Buy |
| 2021-01-04 | 재확인 | H.C. Wainwright | Buy |
| 2019-09-20 | 개시 | B. Riley FBR | Buy |
| 2019-06-10 | 개시 | H.C. Wainwright | Buy |
모두보기
Eton Pharmaceuticals Inc 주식(ETON)의 최신 뉴스
Eton Pharmaceuticals (NASDAQ:ETON) Posts Quarterly Earnings Results, Beats Expectations By $0.07 EPS - MarketBeat
Eton Pharmaceuticals, Inc. (ETON) Q4 Results Fall Short of Projections - Bitget
Eton Pharmaceuticals Q4 Earnings Call Highlights - Yahoo Finance
Eton Pharma (ETON) Earnings Call Transcript - The Globe and Mail
Earnings call transcript: Eton Pharmaceuticals Q4 2025 beats EPS, stock rises - Investing.com
Eton Pharmaceuticals earnings beat by $0.01, revenue fell short of estimates - Investing.com Canada
Eton Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Eton Pharmaceuticals, Inc. (ETON) Q4 Earnings Lag Estimates - Yahoo Finance
ETON PHARMACEUTICALS ($ETON) Releases Q4 2025 Earnings - Quiver Quantitative
Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results - The Manila Times
ETON: 2025 revenues doubled to $80M, but higher costs led to a net loss; growth expected ahead - TradingView
Eton Pharmaceuticals (NASDAQ: ETON) outlines rare-disease drugs, pipeline and IRA pricing risks - Stock Titan
BRIEF-Eton Pharmaceuticals Q4 Net Income USD 1.483 Million - TradingView
After an 83% sales jump, Eton says 2026 revenue will top $110M - Stock Titan
Eton Pharmaceuticals (NASDAQ:ETON) Shares Up 5.8%Time to Buy? - MarketBeat
Analysts’ Top Healthcare Picks: Eton Pharmaceuticals (ETON), Zenas BioPharma, Inc. (ZBIO) - The Globe and Mail
Aug Outlook: What drives Eton Pharmaceuticals Incs stock priceDividend Hike & Free Technical Confirmation Trade Alerts - baoquankhu1.vn
Divisadero Street Capital Management LP Trims Stock Holdings in Eton Pharmaceuticals, Inc. $ETON - MarketBeat
Cannell Capital LLC Buys 67,230 Shares of Eton Pharmaceuticals, Inc. $ETON - MarketBeat
Why (ETON) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Eton Pharmaceuticals (NASDAQ:ETON) Trading Up 6%What's Next? - MarketBeat
Jefferies Financial Group Inc. Invests $1.92 Million in Eton Pharmaceuticals, Inc. $ETON - MarketBeat
Eton Pharmaceuticals (ETON) Expected to Announce Earnings on Thursday - MarketBeat
ETON Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Chipmakers Recap: Is Eton Pharmaceuticals Inc still a buy after recent gainsWeekly Stock Report & Daily Volume Surge Signals - baoquankhu1.vn
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Will Eton Pharmaceuticals Inc. stock deliver strong dividend growth2026 Rallies & Daily Volume Surge Signals - Naître et grandir
Retail Surge: Can Eton Pharmaceuticals Inc lead its sector in growth2025 Trading Recap & Long-Term Capital Growth Strategies - baoquankhu1.vn
HC Wainwright Analysts Boost Earnings Estimates for ETON - MarketBeat
HC Wainwright Issues Pessimistic Outlook for ETON Earnings - MarketBeat
Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, March 19, 2026 - The Manila Times
Eton Pharmaceuticals Announces Fourth Quarter and Full Year 2025 Financial Results Date and Conference Call Details - Quiver Quantitative
Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, ... - Bluefield Daily Telegraph
Eton inks deal to sell its 10th rare disease drug - Crain's Chicago Business
Craig Hallum Issues Positive Forecast for Eton Pharmaceuticals (NASDAQ:ETON) Stock Price - MarketBeat
Eton Pharmaceuticals price target raised to $30 from $29 at Craig-Hallum - TipRanks
Eton Pharmaceuticals acquires U.S. rights to hemangioma drug By Investing.com - Investing.com Canada
Analysts Conflicted on These Healthcare Names: Denali Therapeutics (DNLI), Eton Pharmaceuticals (ETON) and Intellia Therapeutics (NTLA) - The Globe and Mail
Eton Pharmaceuticals acquires U.S. rights to hemangioma drug - Investing.com Australia
Eton Gains on Acquiring Right to Baby Medicine - Baystreet.ca
Eton Pharmaceuticals Acquires US Commercialization Rights to Pierre Fabre's Hemangeol - marketscreener.com
HC Wainwright Forecasts Strong Price Appreciation for Eton Pharmaceuticals (NASDAQ:ETON) Stock - MarketBeat
Eton Pharmaceuticals Acquires U.S. Rights to HEMANGEOL - TipRanks
Eton Pharmaceuticals, Inc. announced that, in addition to the acquisition of core assets, the company also plans to purchase approximately $1.5 million worth of inventory products at the time of transaction closing. - Bitget
Eton Pharmaceuticals Secures U.S. Rights to HEMANGEOL® for Infantile Hemangioma Treatment, Launching May 1st - Quiver Quantitative
Eton Pharmaceuticals Expands Rare Disease Portfolio Through Acquisition of U.S. Commercialization Rights to HEMANGEOL® (propranolol hydrochloride) Oral Solution - The Manila Times
Understanding Momentum Shifts in (ETON) - Stock Traders Daily
Lumbard & Kellner LLC Buys New Holdings in Eton Pharmaceuticals, Inc. $ETON - MarketBeat
Eton Pharmaceuticals Expands Rare Disease Portfolio Through - GlobeNewswire
Eton Pharmaceuticals (NASDAQ: ETON) licenses U.S. HEMANGEOL rights in orphan drug deal - Stock Titan
Eton Pharmaceuticals Inc (ETON) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.02%
0.77%
자본화:
|
볼륨(24시간):